Declaration of interest: The authors have no conflict of interests to declare.
Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis
Article first published online: 31 JAN 2013
© 2013 Japanese Society of Neurology and Wiley Publishing Asia Pty Ltd
Neurology and Clinical Neuroscience
Volume 1, Issue 1, pages 32–37, January 2013
How to Cite
Tetsuka, S., Morita, M., Ikeguchi, K. and Nakano, I. (2013), Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis. Neurology & Clinical Neurosc, 1: 32–37. doi: 10.1002/ncn3.11
- Issue published online: 31 JAN 2013
- Article first published online: 31 JAN 2013
- Manuscript Accepted: 26 NOV 2012
- Research Committee of CNS Degenerative Diseases
- Ministry of Health, Labour and Welfare of Japan
- amyotrophic lateral sclerosis;
- cystatin C;
- residual muscle mass;
- surrogate maker
Identification of sensitive surrogate markers that indicate disease progression in amyotrophic lateral sclerosis might be useful in clinical trials and clinical care. Determination of the creatinine/cystatin C (Cr/CysC) ratio eliminates the effect of renal function on serum creatinine levels; therefore, we considered that the ratio might serve as a surrogate marker of residual muscle mass. We studied the Cr/CysC ratio as a useful surrogate marker of residual muscle mass in patients with amyotrophic lateral sclerosis.
A total of 103 participants were recruited: 62 patients with amyotrophic lateral sclerosis and 41 healthy controls. Serum levels of Cr and CysC were measured in both groups. We subsequently investigated the correlation between the Cr/CysC ratio and disease severity in patients with amyotrophic lateral sclerosis.
The ratio was significantly lower in the amyotrophic lateral sclerosis group than in the control group. Furthermore, the ratio decreased as the severity of amyotrophic lateral sclerosis increased. The Cr/CysC ratio might be a better and more reliable method than the serum Cr level as a means of monitoring residual muscle mass of the entire body in patients with amyotrophic lateral sclerosis.
The present results show that the Cr/CysC ratio might be a suitable candidate for a useful and quantitative surrogate marker for the assessment of disease severity and progression in patients with amyotrophic lateral sclerosis.